Mega Doctor News
EDINBURG, Texas – Prostate cancer is one of the most treatable cancers when found in its early stages. To support early and accurate detection, DHR Health now offers Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection), a prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging tracer for the detection of prostate cancer. This innovative technology is now available for identifying and locating prostate cancer in men whose cancer may have spread to other parts of the body and may need initial therapy, or whose cancer may have come back based on elevated serum prostate-specific antigen (PSA) levels. A PET scan with Illuccix can reveal the presence of prostate cancer cells throughout the body and may be able to detect tumors more accurately than conventional imaging methods. Illuccix is also approved to determine if PSMA-directed radioligand therapy may be appropriate.
More than 3.1 million men are living with prostate cancer in the United States. Prostate cancer continues to pose a significant health challenge, ranking as the second leading cause of cancer death among males. Delayed diagnosis can result in fewer treatment options and increased mortality risk. Ongoing PSA screenings and access to advanced imaging such as a PSMA-PET scan with Illuccix are crucial factors for early detection and accurate diagnosis. Illuccix may be able to detect cancer when PSA levels are low, when tumors are small, or when conventional imaging results are uncertain.
“PSMA-PET/CT technology is a breakthrough in prostate cancer diagnosis,” said Marissa Castaneda, DHR Health senior executive vice president. “Understanding the extent of the disease is crucial in determining the appropriate treatment. A PSMA-PET scan with Illuccix can provide the precision and reliability required to guide treatment decisions for my patients.”
With the addition of this state-of-the-art technology, DHR Health is dedicated to staying at the forefront of medical innovation to provide the best possible healthcare to residents of the Rio Grande Valley.
“The introduction of Illuccix is a significant milestone in our commitment to enhance patient care and outcomes for prostate cancer patients,” said Castaneda.
If you or a family member is interested in getting Illuccix imaging, speak to a urologist, oncologist, or primary care doctor. The physician will review a patients medical history, PSA level, prior treatments to determine if Illuccix imaging is the most appropriate next step of care.
Are you in need of a primary care physician?
DHR Health makes it easy with four convenient Family Medicine and Internal Medicine Clinic locations across Edinburg and McAllen. Our physicians are here to help provide the care your needs. Visit us at: DHR Health Family Medicine Clinic at 1601 E. Sprague in Edinburg, for appointment call (956) 362-8383; DHR Health Family Medicine Clinic located at 1000 E. Dove Avenue, Suite 200 in McAllen, for appointment call (956) 362-3530; DHR Health Internal Medicine Clinic at 801 E. Nolana, Suite 2, in McAllen; and DHR Health Internal Medicine Clinic located at 1000 E. Dove Avenue, Suite 201, in McAllen, for appointment call (956) 362-3530.
